Abstract P6-13-04: Metformin for the treatment of ductal carcinoma in situ (DCIS)
BACKGROUND: Each year about 60,000 new cases of breast ductal carcinoma in situ (DCIS) are diagnosed in the United States. DCIS significantly increases the risk of invasive breast cancer. To reduce this risk, tamoxifen is offered to patients with ER-positive DCIS in the adjuvant setting. In contrast, no adjuvant therapy exists for ER-negative DCIS. Metformin is a frontline therapy for type 2 diabetes and its safety and side effect profiles are well documented. Preclinical, epidemiologic, and retrospective data all support an antitumor effect of metformin in breast cancer. Metformin may act via activation of AMP kinase (AMPK), a sensor of cellular energy, which in turn inhibits mTOR activity and shuts down global protein synthesis. Previous data from our group showed that metformin treatment is associated with a higher rate of pathologic complete response in diabetic breast cancer patients receiving preoperative chemotherapy. In the current study, using preclinical models, we explored the effects of metformin in DCIS and its progression to invasive breast cancer. EXPERIMENTAL DESIGN AND METHODS: We tested the anti-tumor activity of metformin in terms of proliferation and invasion using both DCIS cell lines and a mouse intraductal (MIND) transplantation model previously developed by us. The latter involves intraductal injection of human DCIS cells into mouse mammary glands, and importantly recapitulates the progression of DCIS to invasive cancer seen in human breast cancer. Wes...
Authors: DiCaprio MR, Abousayed MM, Kambam MLR Abstract Melanoma is an aggressive form of skin cancer associated with significant morbidity and mortality. Although commonly seen in dermatologist clinics, orthopaedic surgeons must be aware of these lesions in various ways. The five common musculoskeletal manifestations of melanoma will be discussed as well as the epidemiology, pathogenesis, diagnosis, staging, treatment, and prognosis of melanoma. With an index of suspicion and awareness of melanoma, a thorough history and detailed physical examination are critical in establishing a diagnosis. An adequately performe...
Publication date: Available online 25 February 2020Source: Reports of Practical Oncology &RadiotherapyAuthor(s): Milan Vošmik, Miroslav Hodek, David Buka, Petra Sýkorová, Jakub Grepl, Petr Paluska, Simona Paulíková, Igor Sirák
Publication date: Available online 26 February 2020Source: Practical Radiation OncologyAuthor(s): Kimberly R. Gergelis, Cole R. Kreofsky, Christopher S. Choo, Jason Viehman, W Scott Harmsen, Scott C. Lester, Thomas M. Pisansky, Brian J. Davis, Bradley J. Stish, Richard Choo
Publication date: April 2020Source: Cancer Genetics, Volume 242Author(s):
Publication date: Available online 26 February 2020Source: Cancer GeneticsAuthor(s): Stewart G. Neill, Jennifer Hauenstein, Marilyn M. Li, Yajuan J Liu, Minjie Luo, Debra F. Saxe, Azra H. Ligon
Date: Friday, 02 28, 2020; Speaker: Dr. Weiping Zou, Professor of Pathology, Immunology, Biology&Surgery, University of Michigan School of Medicine; Building: NCI at Frederick, Building 549
CONCLUSION: Ultrasound and MRI have similar diagnostic performance for detecting parametrial infiltration in women with cervical cancer. This might have relevance from the clinical point of view, since ultrasound is cheaper than MRI. PMID: 32096793 [PubMed - as supplied by publisher]
CONCLUSION: By using the combination of ultrasound modes, this approach achieves high performance compared with the single mode and other fusion strategies. Our methodology may be a beneficial tool for the early detection and diagnosis of breast cancer. PMID: 32096788 [PubMed - as supplied by publisher]
CONCLUSIONS: In cases of BCCs with thickness of ≤1 mm, there was a high correlation (r=0.870) of the tumor spread depth between micromorphological measurements and the results obtained using a 75 MHz transducer and in cases of BCCs with thickness of>1 mm, a very high correlation (r=0.951) of the tumor spread depth was observed between histomorphometry and30 MHz transducer measurements. PMID: 32096785 [PubMed - as supplied by publisher]
In this study we report the contribution and prognostic significance of GSK3B to two breast cancer subtypes; ductal carcinoma in-situ (DCIS) and invasive ductal carcinoma (IDC) using the Oncomine platform. We performed high throughput screening using molecular docking. We identified BT-000775, a compound that was subjected to further computational hit optimization protocols. Through computational predictions, BT-000775 is a highly selective GSK3B inhibitor, with superior binding affinity and robust ADME profiles suitable for the patho-physiological presentations. PMID: 31354196 [PubMed]